AREVA receives a DoD grant for research on immunomodulation therapy to improve outcomes for severe burn and trauma patients.
Quiver AI Summary
The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical announced the receipt of a significant grant from the U.S. Department of Defense for research on reducing inflammation in severe burn victims. This grant, one of four awarded from 160 submissions by the 2024 Military Burn Research Program, includes over $2 million in funding for a three-year study starting in July 2025. The research will focus on SeaStar Medical's Selective Cytopheretic Device (SCD) therapy, aimed at mitigating hyperinflammation in military personnel and civilian patients suffering from burn and inhalation injuries. The SCD therapy, which works in conjunction with continuous renal replacement therapy, seeks to improve organ recovery and potentially reduce dialysis needs. Experts involved in the research emphasize its potential to save lives and enhance recovery for critically injured patients. The Geneva Foundation will assist with research administration to support the program's success.
Potential Positives
- The award of a grant from the Department of Defense for a three-year research study signifies strong validation of SeaStar Medical’s technology and research capabilities.
- The grant funding of over $2 million enables further exploration of the Selective Cytopheretic Device (SCD) therapy, potentially enhancing the company’s reputation within military and medical communities.
- The collaboration with the Autonomous Reanimation and Evacuation Research Institute allows SeaStar Medical to participate in cutting-edge research with implications for both military and civilian patient outcomes.
- The press release highlights SeaStar Medical’s innovative SCD therapy, which has received multiple FDA Breakthrough Device Designations, emphasizing its potential impact on treating severe inflammatory conditions and expanding the company's market opportunities.
Potential Negatives
- While the grant represents a significant opportunity, the press release highlights that the success of the SCD therapy remains subject to various significant risks and uncertainties, including regulatory approval and the ability to raise sufficient capital for operations.
- The emphasis on the potential benefits of the SCD therapy may lead to heightened expectations that could negatively impact the company's reputation if the outcomes do not meet these expectations.
- Forward-looking statements mention numerous risks, including the possibility of never achieving profitability and the inability to secure necessary financing, which could pose long-term challenges for the company's operations.
FAQ
What is the purpose of the new DoD grant awarded to AREVA?
The grant supports research on extracorporeal immunomodulation to reduce inflammation after severe burns and traumatic injuries.
How much funding has AREVA received from the DoD?
AREVA has received more than $2 million in DoD funding for the three-year research study.
What technology will be utilized in the study?
The study will explore SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy for reducing hyperinflammation.
Who is the principal investigator for the AREVA study?
Dr. Andriy Batchinsky is the Principal Investigator and Founder of AREVA overseeing the research study.
What is the goal of the SCD therapy in this research?
The SCD therapy aims to improve survival rates and promote organ recovery in trauma and infection cases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- JOHN NEUMAN purchased 10,000 shares for an estimated $20,405
- JENNIFER A BAIRD purchased 10,000 shares for an estimated $12,815
- KEVIN CHUNG (Chief Medical Officer) purchased 4,500 shares for an estimated $5,625
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (Nasdaq: ICU) announced today that a new United States Department of Defense (DoD) grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program (MBRP) and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia.
The grant supports a three-year research study that is scheduled to begin in July 2025 with more than $2 million in DoD funding. The study will explore the application of SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy to reduce hyperinflammation in warfighters after severe burns, inhalation injury, and infection. The award represents a significant step towards the advancement of extracorporeal immunomodulation through the use of the SCD therapy, an innovative therapeutic device designed to neutralize destructive hyperinflammation, to improve survival in both combat casualties and civilian patients suffering from severe trauma and infection. Used alongside continuous renal replacement therapy (CRRT), the SCD therapy is designed to support organ recovery and may reduce the need for dialysis in patients with severe acute inflammatory conditions.
“In my 25-year research career, this particular award and collaboration with SeaStar Medical has the potential to be one of the most impactful,” said Andriy Batchinsky, MD, Principal Investigator and Founder of AREVA. “It may save the lives of large numbers of patients with infection- and trauma-related lung, kidney, and multi-organ failure.”
The Geneva Foundation will provide research administration and operational support to ensure the success of the program at the AREVA Institute in San Antonio, Texas, helping accelerate innovation in military medicine. The grant will cover the purchase of the SCD therapy from SeaStar Medical for use by AREVA in the research study. SeaStar Medical and AREVA are also exploring expanded applications of SeaStar’s technology beyond the initial study.
Kevin Chung, MD, Chief Medical Officer of SeaStar Medical, stated, “The AREVA Institute is one of only a handful of around the clock intensive care unit laboratories in the world capable of delivering this type of work. This DoD award represents a major vote of confidence not only for the AREVA Institute but also the potential of the SCD therapy to play a major role in the care of critically wounded service members. This study will evaluate the ability of the SCD therapy to optimize functional recovery after these types of injuries.”
About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy
The Selective Cytopheretic Device (SCD) therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy has broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous renal replacement therapy (CRRT) hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future RRT, including dialysis, and prevent loss of life.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming the standard of care for critically ill patients at risk of organ failure and death. Its first commercial product, QUELIMMUNE (SCD-PED), received FDA approval in 2024 and is the only approved therapy for pediatric acute kidney injury (AKI) due to sepsis. The company’s SCD therapy has earned six Breakthrough Device Designations from the FDA and is currently in pivotal trials for adult AKI patients requiring CRRT. Learn more at www.seastarmedical.com or follow SeaStar Medical on LinkedIn and X .
About The Geneva Foundation
The Geneva Foundation advances operationally relevant, military-unique research aligned with DoD requirements to ensure mission success. Geneva accelerates military medical R&D to deliver deployable solutions that enhance the health, readiness, and capabilities of service members and the communities they serve. With deep expertise in research operations, government contracting, strategic collaborations, and commercialization, Geneva ensures successful research outcomes and remains a committed strategic partner in advancing military medicine. Learn more: The Geneva Foundation .
SeaStar Medical Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the ability of SCD to save the lives of large numbers of patients with infection- and trauma-related lung, kidney, and multi-organ failure; promote optimal recovery; and reduce the need for dialysis in patients with severe acute inflammatory conditions; Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
SeaStar Investor Relations:
[email protected]
